1. Home
  2. ILLR vs ENGN Comparison

ILLR vs ENGN Comparison

Compare ILLR & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ILLR
  • ENGN
  • Stock Information
  • Founded
  • ILLR 2015
  • ENGN 1999
  • Country
  • ILLR United States
  • ENGN Canada
  • Employees
  • ILLR N/A
  • ENGN N/A
  • Industry
  • ILLR Investment Managers
  • ENGN
  • Sector
  • ILLR Finance
  • ENGN
  • Exchange
  • ILLR Nasdaq
  • ENGN Nasdaq
  • Market Cap
  • ILLR 79.7M
  • ENGN 321.5M
  • IPO Year
  • ILLR N/A
  • ENGN N/A
  • Fundamental
  • Price
  • ILLR $1.48
  • ENGN $6.52
  • Analyst Decision
  • ILLR
  • ENGN Buy
  • Analyst Count
  • ILLR 0
  • ENGN 8
  • Target Price
  • ILLR N/A
  • ENGN $21.50
  • AVG Volume (30 Days)
  • ILLR 3.3M
  • ENGN 225.5K
  • Earning Date
  • ILLR 11-13-2025
  • ENGN 09-11-2025
  • Dividend Yield
  • ILLR N/A
  • ENGN N/A
  • EPS Growth
  • ILLR N/A
  • ENGN N/A
  • EPS
  • ILLR N/A
  • ENGN N/A
  • Revenue
  • ILLR $45,244,000.00
  • ENGN N/A
  • Revenue This Year
  • ILLR N/A
  • ENGN N/A
  • Revenue Next Year
  • ILLR N/A
  • ENGN N/A
  • P/E Ratio
  • ILLR N/A
  • ENGN N/A
  • Revenue Growth
  • ILLR N/A
  • ENGN N/A
  • 52 Week Low
  • ILLR $0.40
  • ENGN $2.65
  • 52 Week High
  • ILLR $6.52
  • ENGN $11.00
  • Technical
  • Relative Strength Index (RSI)
  • ILLR 85.58
  • ENGN 77.94
  • Support Level
  • ILLR $0.61
  • ENGN $5.52
  • Resistance Level
  • ILLR $0.76
  • ENGN $6.54
  • Average True Range (ATR)
  • ILLR 0.15
  • ENGN 0.55
  • MACD
  • ILLR 0.10
  • ENGN 0.11
  • Stochastic Oscillator
  • ILLR 100.00
  • ENGN 99.17

About ILLR Triller Group Inc. Common Stock

Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: